Synchron

Based in Campbell, California and Melbourne , Australia, Synchron, Inc. is a pioneering technology company building next-generation neuromodulation solutions. Synchron is developing the world's first endovascular neural interface, the Stentrode. Development of this technology platform has been funded in part by grants from the U.S. Defense Advanced... Research Projects Agency (DARPA) and U.S. Department of Defense (DoD). The technology was lauded by then President Barack Obama as highly promising in a public statement. NeuroTechnology Investors subsequently led a Series A round of financing that included METIS innovative. The company, which was spun out of the University of Melbourne , is targeting paralysis due to a range of neurological conditions as a first application. Synchron recently reported on the ability to deliver endovascular neuromodulation stimulation into the brain and are investigating alternative therapeutic applications in Movement Disorders, Stroke and Epilepsy. Stentrode, BrainOS, brainPort, BrainClick and Thought-to-Text are trademarks of Synchron, Inc.Read More